Hims & Hers Health stock extended its fall on Tuesday after the telehealth company's third-quarter earnings report missed Wall Street's expectations for revenue and subscriptions.
Hims reported a loss of 14 cents a share and revenue of $890.4 million, which was a gain of 49% from a year ago. But analysts had expected earnings of 6 cents a share and revenue of $893 million, according to FactSet.
Hims reported a net loss of $33.0 million for the quarter, compared with net income of $15.8 million in the year-ago quarter, and consensus expectations of $13.9 million.
Hims said its subscriber count grew 13% to 2.79 million, while revenue per average subscriber increased 30% to $105. But Wall Street expected 3.04 million subscribers, up from 2.89 million in the second quarter and 2.47 million in the year-ago third quarter.
Shares closed down 16.6% at $19.13 on Tuesday, to its lowest close since May 19, after closing down 11.8% at $22.94 on Monday.
Ryan MacDonald, senior analyst for Needham & Co., lowered his price target for Hims stock to $32, down from $42 after its better-than-expected second-quarter earnings report. He reiterated his Buy rating.
He said that of all the companies he covers that are reporting results this week, "we are most positive on HIMS," saying third-party data continues to show "nice sales momentum, which we expect to be fueled by continued weight loss success." The larger focus will be on the company's future, as Hims bolsters its weight-loss portfolio with its new Eli Lilly & Co. partnership and a potential entry into the peptides market.
Monday's stock decline wiped out its 8% gain on Friday, after it announced an agreement with pharmaceutical giant Eli Lilly to sell the popular GLP-1 weight loss drugs Zepbound and Foundayo through Hims' consumer platform.
The agreement with Lilly allows users to complete a consultation, receive a prescription if their provider agrees it is appropriate, and have the Lilly treatments shipped straight to their home. Self-pay pricing starts at $149 a month for Foundayo, an oral medication, and starts at $299 a month for injectable Zepbound
MacDonald wrote that the agreement gives Hims access to both leading GLP-1 manufacturers by allowing eligible patients to obtain self-pay pricing without leaving the Hims & Hers platform.
That, along with ongoing coverage reductions of GLP-1 weight-loss drugs from employers pushing consumers to direct-to-consumer channels -- "a category led by Hims," the U.S. Health and Human Services Department's interim policy allowing state-licensed pharmacies and physicians to compound six different peptides could contribute to revenue margins "earlier in 2027."
Plus, with Hims' injectable and oral testosterone-replacement therapy expansion announced last month, "we expect these three objectives in combination to deliver both an upside" fourth quarter and full-year outlook ahead of 2027, he wrote.
Hims CEO Andrew Dudum said the company was geared toward owning the customer relationship. "Everything we're doing, from expanding the treatments and specialties we make available, to rolling out an AI-native experience to support every customer's care, informed by leading minds in health and science, is designed to meet that higher bar."
Three key areas driving continued growth are Hims' investment in AI and technology to develop "deeper customer relationships and increasing business efficiencies"; its infrastructure to enable Hims to "enter more complex categories at a faster pace and at a greater scale" than competitors; and its global reach.
As an example, Chief Technology Officer Mo Elshenawy said the AI-native experience the company launched for Hers weight-loss customers quickly increased engagement, with customers "sending three times as many messages on the platform, with AI answering 80% of their questions."
Hims' testosterone-replacement business is scaling faster than any other specialty outside of weight loss, giving the company "real confidence in our ability to expand not only into injectable and oral TRT [hormone treatments] before the end of this year, but also to extend this model across other specialties," Dudum added.
Chief Financial Officer Yemi Okupe said the company made "deliberate strategic decisions" to position the company for durable, multi-year growth, including several planned expansions to its platform in the current quarter will "set us up well heading into 2027."
The 49% growth in third-quarter revenue was Hims' second straight quarter of acceleration, as domestic revenue grew 21% from a year ago to $657.1 million, while international revenue increased 321% to $233.3 million.
For the current fourth quarter, Hims expects revenue of $875 million to $895 million. It projects adjusted earnings before interest, taxes, depreciation, and amortization of $70 million to $90 million, reflecting an adjusted Ebitda margin of 8% to 10%.
Hims & Hers also narrowed its full-year guidance, to a range of $3.13 billion to $3.15 billion, down from $3.1 billion to $3.3 billion in the previous quarter. It lowered its adjusted Ebitda to between $257 million and $277 million, reflecting an adjusted Ebitda margin of 8% to 9%.
Hims' stock is down 41% this year through Tuesday's close, on pace for its worst year since 2021, and down 51% over the past 12 months, according to Dow Jones Market Data.
Comments